株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:喘息 - 日本における医薬品の予測と市場分析

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 314730
出版日 ページ情報 英文 167 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
PharmaPoint:喘息 - 日本における医薬品の予測と市場分析 PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023
出版日: 2014年08月31日 ページ情報: 英文 167 Pages
概要

喘息は、適切な治療によって容易に予防することが可能な疾患ですが、世界で年間25万人もの人が亡くなっています。喘息の治療薬市場は、成長が鈍化し、比較的有効性が高い標準的治療が浸透しています。今後は、生物学的薬剤が市場成長を再形成するだけでなく、喘息治療の個別アプローチという新時代の幕開けが予想されています。

当レポートでは、日本における喘息の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • QOL
  • 症状

第4章 疾患の管理

  • 診断と治療の概要
  • 日本

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 吸入コルチコステロイド薬
  • 長時間作用型β作動薬
  • 吸入コルチコステロイド薬/長時間作用型β作動薬
  • ロイコトリエン修飾物質
  • 短時間作用型β作動薬
  • 標的療法
  • 抗コリン作用薬

第6章 アンメットニーズと機会

  • 概要
  • 重症の喘息を抑えるための個別治療
  • 患者のコンプライアンスの向上
  • 低コストの喘息薬
  • 小児喘息の適切な診断

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤

第8章 市場の見通し

  • 日本

第9章 付録

図表

目次

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

The 2013 base-year market sales of asthma products in Japan were $1.7 billion. A dip in sales caused by the Singulair patent expiry in 2013, as well as the patent expiry of the best-selling ICS/LABA FDCs, GSK's Advair and AstraZeneca's Symbicort, will be offset by eight pipeline product launches, seven of which are targeted biologics. Despite the fact that the target patient pool for these biologic therapies will be relatively limited, as they will target only specific subpopulations of severe asthmatics, they will fulfill some of the major unmet needs for the treatment of severe asthmatics who do not respond to conventional treatment with the ICS and ICS/LABA therapies.

Scope

  • Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Asthma market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Inhaled Corticosteroids
    • 5.3.1. Flovent (fluticasone propionate)
    • 5.3.2. Pulmicort (budenoside)
    • 5.3.3. Other Inhaled Corticosteroids
  • 5.4. Long-Acting Beta-Agonists
    • 5.4.1. Overview
  • 5.5. Inhaled Corticosteroids/Long-Acting Beta-Agonists
    • 5.5.1. Advair (fluticasone propionate/salmeterol xinafoate)
    • 5.5.2. Symbicort (budenoside/formoterol fumarate)
    • 5.5.3. Breo Ellipta (fluticasone furoate/vilanterol trifenatate)
    • 5.5.4. Flutiform (fluticasone propionate/formoterol fumarate)
  • 5.6. Leukotriene Modifiers
    • 5.6.1. Singulair (montelukast)
    • 5.6.2. Other Leukotriene Modifiers
  • 5.7. Short-Acting Beta-Agonists
    • 5.7.1. Overview
    • 5.7.2. Efficacy
    • 5.7.3. Safety
  • 5.8. Targeted Therapies
    • 5.8.1. Xolair (omalizumab)
  • 5.9. Anticholinergics
    • 5.9.1. Spiriva (tiotropium bromide)

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Personalized Therapies to Control Severe Asthma
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Patient Compliance
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Lower Cost of Asthma Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Proper Diagnosis of Asthma in Children
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Fluticasone furoate
    • 7.2.2. Cinquil (reslizumab)
    • 7.2.3. Bosatria (mepolizumab)
    • 7.2.4. Lebrikizumab
    • 7.2.5. Benralizumab
    • 7.2.6. Dupilumab
    • 7.2.7. Quilizumab
    • 7.2.8. Tralokinumab

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Asthma Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Key Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Author/Reviewer
    • 9.6.3. Reviewer
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Country Profile, Asthma Management - Japan
  • Table 7: Leading Treatments for Asthma, 2014
  • Table 8: Product Profile - Flovent
  • Table 9: Efficacy - Flovent Diskus Versus Placebo
  • Table 10: Adverse Events Related to Flovent Diskus
  • Table 11: Flovent SWOT Analysis, 2014
  • Table 12: Product Profile - Pulmicort
  • Table 13: Pulmicort-Associated Adverse Events
  • Table 14: Pulmicort SWOT Analysis, 2014
  • Table 15: Summary of Other Marketed ICSs for Asthma Treatment, 2014
  • Table 16: Product Profile - Advair
  • Table 17: Efficacy - Advair Diskus Versus Its Individual Components
  • Table 18: Advair, Frequency of Drug-Related Adverse Events
  • Table 19: Advair SWOT Analysis, 2014
  • Table 20: Product Profile - Symbicort
  • Table 21: Efficacy - Symbicort Versus Its Individual Components
  • Table 22: Symbicort, Frequency of Drug-Related Adverse Events
  • Table 23: Symbicort SWOT Analysis, 2014
  • Table 24: Product Profile - Breo Ellipta
  • Table 25: Efficacy - Breo Ellipta Versus Flovent
  • Table 26: Safety - Breo Ellipta Versus Flovent
  • Table 27: Breo Ellipta SWOT Analysis, 2014
  • Table 28: Product Profile - Flutiform
  • Table 29: Efficacy - Flutiform Versus Advair
  • Table 30: Safety - Flutiform Versus Advair
  • Table 31: Flutiform SWOT Analysis, 2014
  • Table 32: Product Profile - Singulair
  • Table 33: Efficacy - Singulair+Pulmicort Versus Double-Dose of Pulmicort
  • Table 34: Safety of Singulair+Pulmicort Compared With a Double Dose of Pulmicort
  • Table 35: Singulair SWOT Analysis, 2014
  • Table 36: Overview of the Leading SABAs for Asthma Treatment, 2014
  • Table 37: Efficacy - Nebulized Levalbuterol Versus Nebulized Albuterol
  • Table 38: Adverse Events Related to Nebulized Levalbuterol and Nebulized Albuterol
  • Table 39: Product Profile - Xolair
  • Table 40: Efficacy - Xolair Versus Placebo
  • Table 41: Xolair SWOT Analysis, 2014
  • Table 42: Product Profile - Spiriva
  • Table 43: Efficacy - Spiriva's Versus LABA and Double-Dose ICS
  • Table 44: Adverse Events Related to the Use of Spiriva
  • Table 45: Spiriva SWOT Analysis, 2014
  • Table 46: Unmet Need and Opportunity in Asthma
  • Table 47: Asthma - Late Stage Pipeline, 2014
  • Table 48: Product Profile - Fluticasone Furoate
  • Table 49: Fluticasone Fuorate Efficacy Versus Placebo and Fluticasone Propionate
  • Table 50: Fluticasone Furoate Safety Profile
  • Table 51: Fluticasone Furoate SWOT Analysis, 2014
  • Table 52: Product Profile - Cinquil
  • Table 53: Efficacy of Cinquil Versus Placebo
  • Table 54: Cinquil's Safety Profile
  • Table 55: Cinquil SWOT Analysis, 2014
  • Table 56: Product Profile - Bosatria
  • Table 57: Efficacy of Bosatria Versus Placebo
  • Table 58: Bosatria's Safety Profile
  • Table 59: Bosatria SWOT Analysis, 2012
  • Table 60: Product Profile - Lebrikizumab
  • Table 61: Efficacy of Lebrikizumab Versus Placebo
  • Table 62: Lebrikizumab Safety Profile
  • Table 63: Lebrikizumab SWOT Analysis, 2014
  • Table 64: Product Profile - Benralizumab
  • Table 65: Efficacy of Benralizumab Versus Placebo
  • Table 66: Benralizumab SWOT Analysis, 2014
  • Table 67: Product Profile - Dupilumab
  • Table 68: Efficacy of Dupilumab Versus Placebo
  • Table 69: Dupilumab's Safety Profile
  • Table 70: Dupilumab SWOT Analysis, 2014
  • Table 71: Product Profile - Quilizumab
  • Table 72: Efficacy of Quilizumab Versus Placebo
  • Table 73: Quilizumab SWOT Analysis, 2014
  • Table 74: Product Profile - Tralokinumab
  • Table 75: Efficacy of Tralokinumab Versus Placebo
  • Table 76: Tralokinumab's Safety Profile
  • Table 77: Tralokinumab SWOT Analysis, 2014
  • Table 78: Sales Forecast ($m) for Asthma in Japan, 2013-2023
  • Table 79: Key Events Impacting Sales for Asthma in Japan, 2013-2023
  • Table 80: Global Asthma Market - Drivers and Barriers, 2014
  • Table 81: Asthma Market - Drivers and Barriers in Japan, 2013-2023
  • Table 82: Key Launch Dates
  • Table 83: Key Patent Expiries
  • Table 84: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023
  • Figure 4: Sales for Asthma in Japan by Drug Class, 2013-2023
Back to Top